{"status": "Ok", "redirect_url": "https://www.investor.jnj.com/investor-news/news-details/2026/RYBREVANT-FASPRO-amivantamab-and-hyaluronidase-lpuj-pivotal-data-show-strong-and-durable-responses-in-advanced-head-and-neck-cancer-where-options-remain-limited/default.aspx", "message": "News view counter 769201 successfully enlarged"}